• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低剂量组织型纤溶酶原激活剂溶栓治疗

Thrombolysis with low dose tissue plasminogen activator.

作者信息

Doyle E, Britto J, Freeman J, Munro F, Morton N S

机构信息

Intensive Care Unit, Royal Hospital for Sick Children, Yorkhill, Glasgow.

出版信息

Arch Dis Child. 1992 Dec;67(12):1483-4. doi: 10.1136/adc.67.12.1483.

DOI:10.1136/adc.67.12.1483
PMID:1489229
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1793968/
Abstract

Two cases of vena caval thrombosis in infants were successfully treated with low dose (0.01-0.05 mg/kg/hour) local infusions of tissue plasminogen activator after conventional anticoagulant treatment had been unsuccessful. This approach is useful for clots associated with indwelling intravascular catheters, and a low dose infusion of tissue plasminogen activator as a regional application is recommended to achieve clot lysis with minimal systemic effects.

摘要

两例婴儿腔静脉血栓形成患者在常规抗凝治疗失败后,通过低剂量(0.01 - 0.05毫克/千克/小时)局部输注组织型纤溶酶原激活剂成功治愈。这种方法对于与留置血管内导管相关的血栓有效,建议低剂量输注组织型纤溶酶原激活剂进行局部应用,以在全身影响最小的情况下实现血栓溶解。

相似文献

1
Thrombolysis with low dose tissue plasminogen activator.低剂量组织型纤溶酶原激活剂溶栓治疗
Arch Dis Child. 1992 Dec;67(12):1483-4. doi: 10.1136/adc.67.12.1483.
2
Caval thrombolysis in neonates using low doses of recombinant human tissue-type plasminogen activator.
Anaesth Intensive Care. 1991 Feb;19(1):22-7. doi: 10.1177/0310057X9101900104.
3
Recombinant tissue plasminogen activator for neonatal and pediatric vascular thrombolytic therapy.重组组织型纤溶酶原激活剂用于新生儿和儿童血管溶栓治疗。
J Pediatr Surg. 1993 Oct;28(10):1264-8; discussion 1268-9. doi: 10.1016/s0022-3468(05)80310-0.
4
Recombinant tissue plasminogen activator.重组组织型纤溶酶原激活剂
Neonatal Netw. 1996 Sep;15(6):13-8.
5
[Successful lysis of a septic thrombosis of the superior vena cava using recombinant tissue-plasminogen activator].
Klin Padiatr. 1991 Sep-Oct;203(5):363-5. doi: 10.1055/s-2007-1025454.
6
Management of a large organized intraatrial catheter-tip thrombus in a child with acquired immunodeficiency syndrome using escalating tissue plasminogen activator infusions.使用递增剂量的组织纤溶酶原激活剂输注治疗一名患有获得性免疫缺陷综合征儿童的大型有组织的心房导管尖端血栓。
Pediatr Crit Care Med. 2005 Jan;6(1):79-82. doi: 10.1097/01.PCC.0000149681.08212.2E.
7
Thrombolytic therapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low-dose, slow infusion of tissue-type plasminogen activator.低剂量、缓慢输注组织型纤溶酶原激活剂治疗妊娠合并人工心脏瓣膜血栓形成的溶栓治疗。
Circulation. 2013 Jul 30;128(5):532-40. doi: 10.1161/CIRCULATIONAHA.113.001145. Epub 2013 Jun 28.
8
Plasminogen-enriched pulse-spray thrombolysis with tPA: further developments.使用组织型纤溶酶原激活剂(tPA)的富含纤溶酶原脉冲喷雾溶栓:进一步进展。
J Vasc Interv Radiol. 2000 Nov-Dec;11(10):1353-62. doi: 10.1016/s1051-0443(07)61316-5.
9
Thrombolytic therapy with tissue plasminogen activator for superior vena cava thrombosis in an infant with sepsis.
Acta Paediatr. 2005 Feb;94(2):239-41. doi: 10.1111/j.1651-2227.2005.tb01899.x.
10
Treatment of superior vena cava thrombosis with recombinant tissue type plasminogen activator.
Chest. 1991 May;99(5):1298-301. doi: 10.1378/chest.99.5.1298.

引用本文的文献

1
Management of preterm infants with intracardiac thrombi: use of thrombolytic agents.患有心内血栓的早产儿的管理:溶栓剂的使用。
Paediatr Drugs. 2001;3(12):883-98. doi: 10.2165/00128072-200103120-00002.
2
Treatment of neonatal thrombus formation with recombinant tissue plasminogen activator: six years experience and review of the literature.重组组织型纤溶酶原激活剂治疗新生儿血栓形成:六年经验及文献综述
Arch Dis Child Fetal Neonatal Ed. 2001 Jul;85(1):F18-22. doi: 10.1136/fn.85.1.f18.
3
Pulmonary embolism in parenteral nutrition.肠外营养中的肺栓塞
Arch Dis Child. 1996 Feb;74(2):95-8. doi: 10.1136/adc.74.2.95.
4
Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.阿替普酶。对其在急性心肌梗死以外血管疾病中的药理学及治疗应用的重新评估。
Drugs. 1995 Aug;50(2):289-316. doi: 10.2165/00003495-199550020-00007.
5
Tissue plasminogen activator (alteplase) treatment for femoral artery thrombosis after cardiac catheterisation in infants and children.组织型纤溶酶原激活剂(阿替普酶)治疗婴幼儿和儿童心导管插入术后股动脉血栓形成
Br Heart J. 1993 Oct;70(4):382-5. doi: 10.1136/hrt.70.4.382.

本文引用的文献

1
Thrombolytic therapy: current status (2).溶栓治疗:现状(2)
N Engl J Med. 1988 Jun 16;318(24):1585-95. doi: 10.1056/NEJM198806163182406.
2
Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator.
J Am Coll Cardiol. 1987 Sep;10(3):479-90. doi: 10.1016/s0735-1097(87)80188-2.
3
Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET).组织型纤溶酶原激活剂降低急性心肌梗死死亡率的试验。英-斯堪的纳维亚早期溶栓研究(ASSET)。
Lancet. 1988 Sep 3;2(8610):525-30. doi: 10.1016/s0140-6736(88)92656-6.
4
Guidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. Ontario Medical Association Consensus Group on Thrombolytic Therapy.急性心肌梗死静脉溶栓药物使用指南。安大略省医学协会溶栓治疗共识小组。
CMAJ. 1989 Jun 1;140(11):1289-99.
5
Caval thrombolysis in neonates using low doses of recombinant human tissue-type plasminogen activator.
Anaesth Intensive Care. 1991 Feb;19(1):22-7. doi: 10.1177/0310057X9101900104.
6
Tissue plasminogen activator for the treatment of thromboembolism in infants and children.组织型纤溶酶原激活剂用于治疗婴幼儿和儿童的血栓栓塞症。
J Pediatr. 1991 Mar;118(3):467-72. doi: 10.1016/s0022-3476(05)82170-5.